Sign In
Buy INM
$1.59
+0.0700 (+4.61%)
At Close: Jun 03, 2026
Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?
06:57pm, Thursday, 28'th May 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM
03:00pm, Thursday, 28'th May 2026
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOT
10:48am, Wednesday, 27'th May 2026
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
02:37pm, Monday, 25'th May 2026
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)
11:02am, Wednesday, 20'th May 2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders a
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
06:26pm, Tuesday, 19'th May 2026
BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“I
/C O R R E C T I O N -- InMed Pharmaceuticals/
03:00pm, Tuesday, 19'th May 2026
/C O R R E C T I O N -- InMed Pharmaceuticals/ PR Newswire VANCOUVER, BC and SAN FRANCISCO, May 19, 2026
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon clos
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon closing of the pr
Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline
10:05am, Tuesday, 19'th May 2026
InMed Pharmaceuticals Inc. (NASDAQ:INM) shares are up during Tuesday's premarket session, as the company announced a merger agreement with Mentari Therapeutics.
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
08:00am, Tuesday, 19'th May 2026
Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies Concurrent oversubs
InMed Pharmaceuticals Amends Preferred Investment Options
06:00am, Tuesday, 19'th May 2026
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propr
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
06:00pm, Wednesday, 06'th May 2026
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri
InMed Pharmaceuticals Amends Preferred Investment Options
05:30pm, Monday, 27'th Apr 2026
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
05:04pm, Friday, 27'th Mar 2026
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifyin
